Home Southwest Austin, TX Shattuck Labs COMPANY
Clinical Phase 2
3 open jobs · last seen Oct 23, 2026 · 9 sources
Keywords: antibody inflammatory bowel disease Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Carcinoma Crohn's Disease Acute Myeloid Leukemia Myelodysplastic Syndromes Platinum-resistant Ovarian Cancer Epithelial Ovarian Cancer Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Squamous Cell Carcinoma of the Head and Neck Melanoma Non Small Cell Lung Cancer Urothelial Carcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Squamous Cell Carcinoma of the Anus Squamous Cell Carcinoma of the Cervix Squamous Cell Carcinoma of the Skin Renal Cell Carcinoma Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Mismatch Repair Deficient or MSI-High Solid Tumors Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma of Head and Neck SL-325 SL-172154 SL-279252 Drug: SL-172154 Show all 31 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Clinical Trials Associate Shattuck Labs, Durham, NC, US Oct 6, 2026 Oct 11, 2026 Associate Director, Analytical Sciences (Tech Ops) Durham, NC, US Aug 11, 2026 Oct 11, 2026 Scientist (I, II or Senior), Formulation Sciences (Tech Ops) Durham, NC, US Aug 11, 2026 Oct 11, 2026
See all 3 jobs
At a glance HQ Austin, TX source Region Southwest Stage Clinical Phase 2 Latest trial Phase 2: A Study of SL-325 in Crohn's Disease Patients (2026-10) source Timeline 2026-10 Trial start Phase 2: A Study of SL-325 in Crohn's Disease Patients source ↗ Sep 18, 2025 Trial start 1: Phase 1 Study of SL-325 in Healthy Volunteers source ↗ Aug 26, 2025 Raise Private placement: $103M (up to, as announced), announced Aug 26, 2025. Source: company release on GlobeNewswire. source ↗ Aug 5, 2025 Raise Private placement: $103M (total, as published), announced Aug 5, 2025. Source: SEC filing. source ↗ Aug 18, 2022 Trial start 1: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers source ↗ Mar 17, 2022 Trial start 1: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML source ↗ Sep 17, 2020 Trial start Phase 1: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin source ↗ Jun 29, 2020 Trial start 1: Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer source ↗ Mar 26, 2019 Trial start Phase 1: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas source ↗ Upcoming milestones 2028-07 (ESTIMATED) · Phase 2 · A Study of SL-325 in Crohn's Disease Patients · NCT07753850 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $206.0M. Last 2 years.
Aug 26, 2025 Private placement: $103M (up to, as announced), announced Aug 26, 2025. Source: company release on GlobeNewswire. source ↗ Aug 5, 2025 Private placement: $103M (total, as published), announced Aug 5, 2025. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 7 Record Title Phase Status Start Primary completion NCT07753850 A Study of SL-325 in Crohn's Disease Patients Phase 2 Not yet recruiting 2026-10 2028-07 (estimated) NCT07158437 Phase 1 Study of SL-325 in Healthy Volunteers 1 Active, not recruiting Sep 18, 2025 2026-07 (estimated) NCT05275439 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML 1 Terminated Mar 17, 2022 Feb 6, 2025 (actual) NCT05483933 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers 1 Completed Aug 18, 2022 Feb 7, 2025 (actual) NCT03894618 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase 1 Completed Mar 26, 2019 May 4, 2023 (actual) NCT04502888 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1 Terminated Sep 17, 2020 Apr 8, 2022 (actual) NCT04406623 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer 1 Completed Jun 29, 2020 Feb 2, 2023 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗ Open jobs 3 Title Location (from posting, not HQ) Employer posted First seen Level Clinical Trials Associate Shattuck Labs, Durham, NC, US Oct 6, 2026 Oct 11, 2026 Entry Description Associate Director, Analytical Sciences (Tech Ops) Durham, NC, US Aug 11, 2026 Oct 11, 2026 Senior Description Scientist (I, II or Senior), Formulation Sciences (Tech Ops) Durham, NC, US Aug 11, 2026 Oct 11, 2026 Mid Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Shattuck Labs on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
